US · Healthcare · Diagnostics & Research
EPS came in at 4.84 against a street estimate of 4.45 — a beat of 8.8%.
Analysts rate Medpace Holdings Inc a hold (2 buy, 11 hold, 1 sell out of 14) with an average price target of $651.31.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.93% |
| T. Rowe Price Associates, Inc. | 7.40% |
| AQR Capital Management LLC | 4.57% |
| Vanguard Portfolio Management, LLC | 4.05% |
| Vanguard Capital Management, LLC | 3.67% |
| State Street Corp | 2.54% |
| Geode Capital Management, LLC | 2.54% |
| Wasatch Advisors LP | 2.28% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Q3 2026 revenue was $716,000 thousand, up from $659,903 thousand in Q3 2025. • Q3 2026 net income was $137,460 thousand, versus $ | 2026-10-22 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 revenue rose 8.5% to $716.0 million from $659.9 million; constant-currency growth was 8.6%. • Net new business awards inc | 2026-10-21 |
| Quarterly report · Q2 2026 MEDPACE HOLDINGS, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Six-month net income: $245.2 million (vs. $204.9 million in H1 2025, +19.6%) • Six- | 2026-07-23 |
| Results announced · Q3 2026 MEDPACE HOLDINGS, INC. - Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 revenue: $707.3 million, up 17.2% from $603.3 million in Q2 2025 • Q2 2 | 2026-07-22 |
| Board / officer change · Q2 2026 MEDPACE HOLDINGS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Brad W. Hansman appointed Executive Vice President, Operations effective June 1, 2026 • Annu | 2026-06-04 |
| Charter / bylaws change · Q2 2026 MEDPACE HOLDINGS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 15, 2026 with stockholder votes on 7 proposals • All director nomine | 2026-05-19 |
| Quarterly report · Q1 2026 MEDPACE HOLDINGS, INC. - Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue (Q1 2026): $706.6 million, up 26.5% from $558.6 million in Q1 2025 • N | 2026-04-23 |
| Results announced · Q2 2026 MEDPACE HOLDINGS, INC. – Q1 2026 RESULTS SUMMARY HEADLINE NUMBERS • Q1 2026 Revenue: $706.6 million, up 26.5% year-over-year from $558.6 million in | 2026-04-22 |
Readable in the app.
| Announcement | Date |
|---|---|
| New $1 billion stock repurchase authorization approved through December 2028 Medpace reported its third-quarter and nine-month 2026 financial results, but the announcement provided here does not include the actual revenue, profit, or guidance figures, so those result | 2026-10-21 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Medpace Holdings Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.